Bio­Marin touts Vox­zo­go sales bump in Q2 re­sults, notes 'tem­porar­i­ly tight sup­ply'

Bio­Marin is tout­ing “record rev­enues” from the first half of 2023, spear­head­ed by the jump in sales of its achon­dropla­sia drug Vox­zo­go — so much so that it’s putting a strain on sup­ply.

Vox­zo­go re­mains the star of the show as Bio­Marin is still gear­ing up for the launch of Roc­ta­vian, its gene ther­a­py for he­mo­phil­ia A, in Eu­rope (where it was ap­proved last Au­gust) and the US (fol­low­ing FDA ap­proval just weeks ago). The com­pa­ny ex­pects Roc­ta­vian to be avail­able for com­mer­cial use in the US lat­er this month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER